SCHEMBL11525903

SCHEMBL11525903

O=C(N/C(C(=O)O)=C(/NC(=O)Oc1ccccc1)C(=O)O)Oc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
MAPT P10636 4/20 0.49
RAB9A P51151 1/20 0.47
RAD51 Q06609 1/20 0.47
KDM4E B2RXH2 4/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SLC1A3 P43003 1/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 2/20 0.46
ALOX15 P16050 1/20 0.46
TDP1 Q9NUW8 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
THRB P10828 1/20 0.45
GFER P55789 1/20 0.45
GAA P10253 3/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11525910 1.00 ALDH1A1 (0.49) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL23749590 1.00 ALDH1A1 (0.49) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL2551644 0.87 ALDH1A1 (0.55) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL5279705 0.83 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL3074679 0.83 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL13019613 0.79 ALDH1A1 (0.62) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL2186384 0.79 SLC1A3 (0.50) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL26940022 0.79 ALDH1A1 (0.49) ALDH1A1MAPTRAB9ARAD51KDM4E
SCHEMBL16293318 0.79 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ARAD51HSD17B10
SCHEMBL3063928 0.78 NFKB1 (0.49) ALDH1A1MAPTRAB9ARAD51KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4103640-B1 NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF NOVOCHIZOL SA (CH) 2025-02-26 EP disclosed
US-20230096466-A1 NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF NOVOCHIZOL SA (CH) 2023-03-30 US disclosed
CN-115516012-A Novel synthesis method and application of chitosan derivative 诺和席卓股份有限公司 2022-12-23 CN disclosed
EP-4103640-A1 NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF Novochizol SA (CH) 2022-12-21 EP disclosed
WO-2021160667-A1 NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF NOVOCHIZOL SA (CH) 2021-08-19 WO disclosed
EP-3865535-A1 NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF Bosti Trading Ltd. (CY) 2021-08-18 EP disclosed
US-4160866-A CROSSLINKERS FOR NATURAL AND SYNTHETIC RUBBERS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230096466-A1 NEW METHOD OF SYNTHESIS OF CHITOSAN DERIVATIVES AND USES THEREOF CHIA, CHIT1, CHI3L2 ALDH1A1 3484/4885MAPT 4193/4885RAB9A 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.